A First-in-Human, Randomized, Double-Blind, Placebo/Active Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases
Latest Information Update: 30 Jan 2023
At a glance
- Drugs YH 35324 (Primary) ; Omalizumab
- Indications Immediate hypersensitivity
- Focus Adverse reactions; First in man
- Sponsors Yuhan
- 26 Jan 2023 Status changed from active, no longer recruiting to completed.
- 12 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2021 New trial record